Economic analysis of tirilazad mesylate for aneurysmal subarachnoid hemorrhage. Economic evaluation of a phase III clinical trial in Europe and Australia.
This study used data from a multinational phase III randomized, double-blind, vehicle-controlled trial to evaluate the cost-effectiveness of tirilazad mesylate (Freedox) in the treatment of aneurysmal subarachnoid hemorrhage. In men, therapy with 6 mg/kg per day of tirilazad mesylate was associated with significantly increased survival, increased cost of care, and ratios of cost per death averted that compare favorably with the ratios of other life and death interventions. In women, it appeared to have no effects on costs or survival. Further clinical studies may provide additional information about the cost-effectiveness of this intervention.
Glick
H
H
University of Pennsylvania, USA.
Willke
R
R
Polsky
D
D
Llana
T
T
Alves
W M
WM
Kassell
N
N
Schulman
K
K
D001315:Australia; D017326:Clinical Trials, Phase III as Topic / Q000191:economics; D003362:Cost-Benefit Analysis; D005060:Europe; D005260:Female; D017721:Hospital Costs / Q000706:statistics & numerical data*; D006761:Hospitals / Q000706:statistics & numerical data; D006801:Humans; D002532:Intracranial Aneurysm / Q000150:complications; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009520:New Zealand; D017063:Outcome Assessment, Health Care; D011281:Pregnatrienes / Q000627:therapeutic use*; D012680:Sensitivity and Specificity; D013345:Subarachnoid Hemorrhage / Q000188:drug therapy* / Q000209:etiology
D018696:Neuroprotective Agents; D011281:Pregnatrienes; C053355:tirilazad